Table 1.
Subject characteristics at entry into study.
| SUBJECT BASELINE CHARACTERISTICS | Placebo Treated (N=33) |
Isoflavone Treated (N=32) |
P-value |
|---|---|---|---|
| Age in years: mean (SD) | 76.8 (6.8) | 75.7 (7.7) | 0.54 |
| Gender: Percent and number of Women | 51.5% (n=17) | 53.1% (n=17) | 0.90 |
| Education in years: mean (SD) | 14.2 (2.5) | 14.8 (2.7) | 0.38 |
| ApoE4 Status1: Percent and number of ApoE4 carriers | 45.4% (n=15) | 50.0% (n=16) | 0.71 |
| Total weekly Isoflavone intake at Baseline2: mean mg/week (SD) | 6.5 (34.1) | 16.5 (66.3) | 0.45 |
| Global Cognition: Mini-Mental State Examination score mean (SD) | 22.4 (5.3) | 23.5 (4.0) | 0.35 |
| Mood Symptoms: Geriatric Depression Scale-Short Form score mean (SD) | 2.6 (2.4) | 3.2 (3.3) | 0.40 |
| Concomitant treatment: Percent and number on AchE-I3 | 90.9% (n=30) | 96.9% (n=31) | 0.32 |
| Concomitant treatment: Percent and number on NMDA-receptor blocker4 | 42.4% (n=14) | 50.0% (n=16) | 0.54 |
| Body Mass Index | 27.9 (5.4) | 27.5 (5.0) | 0.75 |
1
One subject in each group declined to undergo ApoE genotyping
2
Established with Food Frequency Questionnaire (FFQ)
3
Acetylcholinesterase-Inhibitors included Donepezil, Galantamine Hydrobromide, and Rivastigmine
4
NMDA-Receptor Blocker was Memantine